JP7656548B2 - 痛風または高尿酸血症を処置するための化合物 - Google Patents

痛風または高尿酸血症を処置するための化合物 Download PDF

Info

Publication number
JP7656548B2
JP7656548B2 JP2021568229A JP2021568229A JP7656548B2 JP 7656548 B2 JP7656548 B2 JP 7656548B2 JP 2021568229 A JP2021568229 A JP 2021568229A JP 2021568229 A JP2021568229 A JP 2021568229A JP 7656548 B2 JP7656548 B2 JP 7656548B2
Authority
JP
Japan
Prior art keywords
compound
formula
pharma
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021568229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533958A (ja
JP2022533958A5 (https=
JPWO2020232156A5 (https=
Inventor
イェン，シュンチー
イェー，リテイン
ヤン，ロンジ
シェン，ザンコン
Original Assignee
アースローシ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アースローシ セラピューティクス，インク． filed Critical アースローシ セラピューティクス，インク．
Publication of JP2022533958A publication Critical patent/JP2022533958A/ja
Publication of JP2022533958A5 publication Critical patent/JP2022533958A5/ja
Publication of JPWO2020232156A5 publication Critical patent/JPWO2020232156A5/ja
Application granted granted Critical
Publication of JP7656548B2 publication Critical patent/JP7656548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
JP2021568229A 2019-05-14 2020-05-13 痛風または高尿酸血症を処置するための化合物 Active JP7656548B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847519P 2019-05-14 2019-05-14
US62/847,519 2019-05-14
PCT/US2020/032725 WO2020232156A1 (en) 2019-05-14 2020-05-13 Compound for treating gout or hyperuricemia

Publications (4)

Publication Number Publication Date
JP2022533958A JP2022533958A (ja) 2022-07-27
JP2022533958A5 JP2022533958A5 (https=) 2023-05-15
JPWO2020232156A5 JPWO2020232156A5 (https=) 2023-05-15
JP7656548B2 true JP7656548B2 (ja) 2025-04-03

Family

ID=73288915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021568229A Active JP7656548B2 (ja) 2019-05-14 2020-05-13 痛風または高尿酸血症を処置するための化合物

Country Status (14)

Country Link
US (1) US20220242841A1 (https=)
EP (1) EP3968989A4 (https=)
JP (1) JP7656548B2 (https=)
KR (1) KR20220016105A (https=)
CN (1) CN113874014A (https=)
AU (2) AU2020274165A1 (https=)
BR (1) BR112021022843A2 (https=)
CA (1) CA3140412A1 (https=)
IL (1) IL288034B1 (https=)
MA (1) MA55973A (https=)
MX (1) MX2021013980A (https=)
SG (1) SG11202112562XA (https=)
TW (1) TW202108561A (https=)
WO (1) WO2020232156A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105743RA (en) 2018-12-06 2021-06-29 Arthrosi Therapeutics Inc Methods for treating or preventing gout or hyperuricemia
KR102946486B1 (ko) 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
KR20230024354A (ko) * 2020-06-10 2023-02-20 아쓰로시 테라퓨틱스, 인크. 만성 신장 질환을 치료 또는 예방하는 방법
WO2023058975A1 (ko) * 2021-10-07 2023-04-13 (주)이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물
TW202330485A (zh) * 2021-12-02 2023-08-01 美商安索治療公司 用於治療或預防痛風或高尿酸血症之化合物的結晶形式
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia
US20250242050A1 (en) 2024-01-31 2025-07-31 The Industry & Academic Cooperation In Chungnam National University (Iac) Composition for treating gout containing cyclodextrin-conjugated polymer nano-drug and method for treating gout

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017368A1 (en) 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
US20210130312A1 (en) * 2018-04-03 2021-05-06 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
KR102946486B1 (ko) * 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017368A1 (en) 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Drug Metab. Pharmacokinet.，2017年，３２，４６－５２
J. Biochem. Mol. Toxicol. ，2017年，３１，pp.e21946(1-5)
J. Chromatogr. B，2012年，９１１，１２２－１３２
Xenobiotica ，1993年，２３，１４３５－１４５０

Also Published As

Publication number Publication date
JP2022533958A (ja) 2022-07-27
MA55973A (fr) 2022-03-23
CN113874014A (zh) 2021-12-31
BR112021022843A2 (pt) 2022-03-03
WO2020232156A1 (en) 2020-11-19
KR20220016105A (ko) 2022-02-08
EP3968989A4 (en) 2022-12-28
IL288034B1 (en) 2026-04-01
SG11202112562XA (en) 2021-12-30
IL288034A (en) 2022-01-01
EP3968989A1 (en) 2022-03-23
MX2021013980A (es) 2022-04-01
TW202108561A (zh) 2021-03-01
AU2026202224A1 (en) 2026-04-09
AU2020274165A1 (en) 2022-01-06
CA3140412A1 (en) 2020-11-19
US20220242841A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
JP7656548B2 (ja) 痛風または高尿酸血症を処置するための化合物
JP7528080B2 (ja) 痛風または高尿酸血症を処置または予防するための方法
US20250059150A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
US20250066316A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
KR102956127B1 (ko) 통풍 또는 고뇨산혈증의 치료 또는 예방 방법
EA049585B1 (ru) Соединение для лечения подагры или гиперурикемии
US12612401B2 (en) Crystalline forms of an S1P receptor modulator
US20240010649A1 (en) Crystalline forms of an s1p receptor modulator
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia
HK40060723A (en) Compound for treating gout or hyperuricemia
CA3121913C (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250324

R150 Certificate of patent or registration of utility model

Ref document number: 7656548

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150